Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Jia Jie Biomedical

GTSM:4109
Snowflake Description

Flawless balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
4109
GTSM
NT$827M
Market Cap
  1. Home
  2. TW
  3. Household
Company description

Jia Jie Biomedical Co., Ltd. provides natural terrapin related nutrition supplements in Taiwan, Japan, and Mainland China. The last earnings update was 11 days ago. More info.


Add to Portfolio Compare Print
  • Jia Jie Biomedical has significant price volatility in the past 3 months.
4109 Share Price and Events
7 Day Returns
0.8%
GTSM:4109
3.9%
TW Personal Products
4.9%
TW Market
1 Year Returns
-48.8%
GTSM:4109
-32.6%
TW Personal Products
-7.7%
TW Market
4109 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Jia Jie Biomedical (4109) 0.8% -34.6% -38% -48.8% -52.5% -55.3%
TW Personal Products 3.9% -11% -22.1% -32.6% -10.7% 13.2%
TW Market 4.9% -7.9% -15.3% -7.7% 1.3% 4.7%
1 Year Return vs Industry and Market
  • 4109 underperformed the Personal Products industry which returned -32.6% over the past year.
  • 4109 underperformed the Market in Taiwan, Province of China which returned -7.7% over the past year.
Price Volatility
4109
Industry
5yr Volatility vs Market

Value

 Is Jia Jie Biomedical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Jia Jie Biomedical to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Jia Jie Biomedical.

GTSM:4109 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 5.8%
Perpetual Growth Rate 10-Year TW Government Bond Rate 0.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for GTSM:4109
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year TW Govt Bond Rate 0.7%
Equity Risk Premium S&P Global 6.2%
Personal Products Unlevered Beta Simply Wall St/ S&P Global 0.68
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.684 (1 + (1- 20%) (10.27%))
0.826
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.83
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.71% + (0.826 * 6.21%)
5.84%

Discounted Cash Flow Calculation for GTSM:4109 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Jia Jie Biomedical is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

GTSM:4109 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (TWD, Millions) Source Present Value
Discounted (@ 5.84%)
2020 41.42 Est @ 100.23% 39.13
2021 70.57 Est @ 70.38% 62.99
2022 105.48 Est @ 49.48% 88.97
2023 142.24 Est @ 34.85% 113.35
2024 177.24 Est @ 24.61% 133.45
2025 208.14 Est @ 17.44% 148.07
2026 233.99 Est @ 12.42% 157.28
2027 254.83 Est @ 8.91% 161.84
2028 271.26 Est @ 6.45% 162.77
2029 284.08 Est @ 4.73% 161.06
Present value of next 10 years cash flows NT$1,228.00
GTSM:4109 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= NT$284.08 × (1 + 0.71%) ÷ (5.84% – 0.71%)
NT$5,577.81
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= NT$5,577.81 ÷ (1 + 5.84%)10
NT$3,162.27
GTSM:4109 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= NT$1,228.00 + NT$3,162.27
NT$4,390.27
Equity Value per Share
(TWD)
= Total value / Shares Outstanding
= NT$4,390.27 / 68.94
NT$63.69
GTSM:4109 Discount to Share Price
Calculation Result
Value per share (TWD) From above. NT$63.69
Current discount Discount to share price of NT$12.00
= -1 x (NT$12.00 - NT$63.69) / NT$63.69
81.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Jia Jie Biomedical is available for.
Intrinsic value
>50%
Share price is NT$12 vs Future cash flow value of NT$63.69
Current Discount Checks
For Jia Jie Biomedical to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Jia Jie Biomedical's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Jia Jie Biomedical's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Jia Jie Biomedical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Jia Jie Biomedical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
GTSM:4109 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in TWD NT$-0.36
GTSM:4109 Share Price ** GTSM (2020-04-09) in TWD NT$12
Taiwan, Province of China Personal Products Industry PE Ratio Median Figure of 14 Publicly-Listed Personal Products Companies 13.39x
Taiwan, Province of China Market PE Ratio Median Figure of 1,476 Publicly-Listed Companies 14.6x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Jia Jie Biomedical.

GTSM:4109 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= GTSM:4109 Share Price ÷ EPS (both in TWD)

= 12 ÷ -0.36

-33.33x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Jia Jie Biomedical is loss making, we can't compare its value to the TW Personal Products industry average.
  • Jia Jie Biomedical is loss making, we can't compare the value of its earnings to the Taiwan, Province of China market.
Price based on expected Growth
Does Jia Jie Biomedical's expected growth come at a high price?
Raw Data
GTSM:4109 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -33.33x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Asia Personal Products Industry PEG Ratio Median Figure of 43 Publicly-Listed Personal Products Companies 2.43x
Taiwan, Province of China Market PEG Ratio Median Figure of 183 Publicly-Listed Companies 1.16x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Jia Jie Biomedical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Jia Jie Biomedical's assets?
Raw Data
GTSM:4109 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in TWD NT$10.67
GTSM:4109 Share Price * GTSM (2020-04-09) in TWD NT$12
Taiwan, Province of China Personal Products Industry PB Ratio Median Figure of 23 Publicly-Listed Personal Products Companies 1.49x
Taiwan, Province of China Market PB Ratio Median Figure of 1,962 Publicly-Listed Companies 1.22x
GTSM:4109 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= GTSM:4109 Share Price ÷ Book Value per Share (both in TWD)

= 12 ÷ 10.67

1.13x

* Primary Listing of Jia Jie Biomedical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Jia Jie Biomedical is good value based on assets compared to the TW Personal Products industry average.
X
Value checks
We assess Jia Jie Biomedical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Personal Products industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Personal Products industry average (and greater than 0)? (1 check)
  5. Jia Jie Biomedical has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Jia Jie Biomedical expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Jia Jie Biomedical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
12.1%
Expected Personal Products industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Jia Jie Biomedical expected to grow at an attractive rate?
  • Unable to compare Jia Jie Biomedical's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Jia Jie Biomedical's earnings growth to the Taiwan, Province of China market average as no estimate data is available.
  • Unable to compare Jia Jie Biomedical's revenue growth to the Taiwan, Province of China market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
GTSM:4109 Future Growth Rates Data Sources
Data Point Source Value (per year)
Asia Personal Products Industry Earnings Growth Rate Market Cap Weighted Average 12.1%
Asia Personal Products Industry Revenue Growth Rate Market Cap Weighted Average 6.5%
Taiwan, Province of China Market Earnings Growth Rate Market Cap Weighted Average 11%
Taiwan, Province of China Market Revenue Growth Rate Market Cap Weighted Average 6.6%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
GTSM:4109 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in TWD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
GTSM:4109 Past Financials Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income *
2019-12-31 343 25 -24
2019-09-30 356 31 30
2019-06-30 384 21 32
2019-03-31 394 6 3
2018-12-31 402 3 2
2018-09-30 446 -18 -245
2018-06-30 459 -34 -263
2018-03-31 476 -58 -246
2017-12-31 522 -14 -232
2017-09-30 523 -33 -20
2017-06-30 529 -33 -6
2017-03-31 577 -1 5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Jia Jie Biomedical is high growth as no earnings estimate data is available.
  • Unable to determine if Jia Jie Biomedical is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
GTSM:4109 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Jia Jie Biomedical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:4109 Past Financials Data
Date (Data in TWD Millions) EPS *
2019-12-31 -0.36
2019-09-30 0.44
2019-06-30 0.46
2019-03-31 0.04
2018-12-31 0.04
2018-09-30 -3.55
2018-06-30 -3.82
2018-03-31 -3.57
2017-12-31 -3.37
2017-09-30 -0.28
2017-06-30 -0.09
2017-03-31 0.07

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Jia Jie Biomedical will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine whether Jia Jie Biomedical is trading at Jia Jie Biomedical'san attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  2. Jia Jie Biomedical's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Household companies here
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Jia Jie Biomedical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Asia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Asia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Jia Jie Biomedical has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Jia Jie Biomedical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Jia Jie Biomedical's growth in the last year to its industry (Personal Products).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Jia Jie Biomedical does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Jia Jie Biomedical's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Jia Jie Biomedical's 1-year growth to the TW Personal Products industry average as it is not currently profitable.
Earnings and Revenue History
Jia Jie Biomedical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Jia Jie Biomedical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:4109 Past Revenue, Cash Flow and Net Income Data
Date (Data in TWD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 343.06 -24.48 110.49 1.92
2019-09-30 355.92 30.36 115.84 2.26
2019-06-30 384.46 31.64 124.06 2.20
2019-03-31 394.36 2.61 138.37 2.14
2018-12-31 402.03 2.47 149.99 2.14
2018-09-30 445.78 -244.62 172.27 2.48
2018-06-30 458.60 -263.33 189.96 2.70
2018-03-31 475.94 -245.88 188.49 2.90
2017-12-31 521.75 -232.09 187.74 3.28
2017-09-30 523.15 -19.64 173.74 3.45
2017-06-30 529.12 -6.32 165.41 3.64
2017-03-31 577.00 5.11 166.20 7.64
2016-12-31 626.06 11.63 173.71 11.50
2016-09-30 728.24 21.34 169.50 18.24
2016-06-30 801.71 33.84 167.45 25.09
2016-03-31 794.55 36.88 168.76 28.07
2015-12-31 797.49 37.84 168.58 30.97
2015-09-30 712.06 29.19 169.99 29.12
2015-06-30 681.33 28.56 171.00 27.22
2015-03-31 645.97 27.17 167.26 24.12
2014-12-31 588.82 20.46 163.29 21.32
2014-09-30 616.14 30.83 174.05 24.00
2014-06-30 602.76 31.86 175.17 19.09
2014-03-31 595.35 24.59 182.59 15.53
2013-12-31 598.20 22.07 179.74 11.70
2013-09-30 622.00 21.13 171.90 7.57
2013-06-30 621.88 20.16 165.80 7.93

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Jia Jie Biomedical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Jia Jie Biomedical has efficiently used its assets last year compared to the TW Personal Products industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Jia Jie Biomedical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Jia Jie Biomedical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Personal Products industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Jia Jie Biomedical has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Jia Jie Biomedical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Jia Jie Biomedical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Jia Jie Biomedical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Jia Jie Biomedical's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Jia Jie Biomedical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Jia Jie Biomedical Company Filings, last reported 3 months ago.

GTSM:4109 Past Debt and Equity Data
Date (Data in TWD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 694.88 62.80 104.38
2019-09-30 709.40 82.79 93.70
2019-06-30 716.16 83.77 93.98
2019-03-31 700.67 166.75 141.10
2018-12-31 714.19 298.60 154.82
2018-09-30 672.29 505.16 183.36
2018-06-30 671.00 522.39 176.03
2018-03-31 694.61 517.25 140.60
2017-12-31 699.60 488.43 137.72
2017-09-30 921.88 480.31 124.78
2017-06-30 937.06 508.90 138.05
2017-03-31 952.05 522.36 182.46
2016-12-31 962.54 550.38 156.70
2016-09-30 954.19 496.46 177.52
2016-06-30 966.38 458.77 202.58
2016-03-31 990.55 409.23 166.13
2015-12-31 983.23 397.40 216.06
2015-09-30 963.32 406.84 187.06
2015-06-30 948.72 406.36 171.81
2015-03-31 977.61 406.24 218.41
2014-12-31 957.39 168.40 215.96
2014-09-30 947.06 52.76 296.08
2014-06-30 930.07 67.91 276.98
2014-03-31 914.62 69.76 251.17
2013-12-31 892.56 91.79 271.16
2013-09-30 729.38 147.48 191.21
2013-06-30 708.52 145.95 219.04
  • Jia Jie Biomedical's level of debt (9%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (17.9% vs 9% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Jia Jie Biomedical has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Jia Jie Biomedical has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -24.7% per year.
X
Financial health checks
We assess Jia Jie Biomedical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Jia Jie Biomedical has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Jia Jie Biomedical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Jia Jie Biomedical dividends.
If you bought NT$2,000 of Jia Jie Biomedical shares you are expected to receive NT$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Jia Jie Biomedical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Jia Jie Biomedical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
GTSM:4109 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Taiwan, Province of China Personal Products Industry Average Dividend Yield Market Cap Weighted Average of 14 Stocks 4.6%
Taiwan, Province of China Market Average Dividend Yield Market Cap Weighted Average of 1335 Stocks 4.4%
Taiwan, Province of China Minimum Threshold Dividend Yield 10th Percentile 1.7%
Taiwan, Province of China Bottom 25% Dividend Yield 25th Percentile 3.1%
Taiwan, Province of China Top 25% Dividend Yield 75th Percentile 6.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

GTSM:4109 Past Annualized Dividends Data
Date (Data in NT$) Dividend per share (annual) Avg. Yield (%)
2019-03-29 0.000 0.000
2018-11-14 0.000 0.000
2018-11-12 0.000 0.000
2018-08-14 0.000 0.000
2018-08-10 0.000 0.000
2018-05-15 0.000 0.000
2018-05-11 0.000 0.000
2018-03-31 0.000 0.000
2018-03-30 0.000 0.000
2017-03-31 0.091 0.427
2016-03-31 0.216 0.912
2015-03-30 0.207 0.807
2014-11-11 0.300 1.237
2014-03-28 0.300 1.156
2014-01-15 0.300 1.105
2013-03-29 0.384 1.657
2013-03-28 0.384 1.677
2012-03-26 0.000 0.000
2011-10-27 0.000 0.000
2011-10-17 0.000 0.000
2011-08-30 0.000 0.000
2011-04-29 0.000 0.000
2011-04-26 0.000 0.000
2011-04-22 0.000 0.000
2010-10-28 0.407 1.665
2010-04-29 0.407 2.042
2010-04-23 0.407 1.953
2010-01-15 0.407 2.629
2009-04-29 0.399 2.520
2009-04-27 0.399 2.597

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Jia Jie Biomedical has not reported any payouts.
  • Unable to verify if Jia Jie Biomedical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Jia Jie Biomedical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Jia Jie Biomedical has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Jia Jie Biomedical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.7%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Jia Jie Biomedical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Jia Jie Biomedical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Jia Jie Biomedical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Jia Jie Biomedical has no CEO, or we have no data on them.
Management Team
Board of Directors
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NT$) Value (NT$)
X
Management checks
We assess Jia Jie Biomedical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Jia Jie Biomedical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Jia Jie Biomedical Co., Ltd. provides natural terrapin related nutrition supplements in Taiwan, Japan, and Mainland China. The company offers Terrapin Capsules-P; Remain Young; Neoenergy; Golden Energy capsules; Pine Hisens; Li-R Bao, ER Mei, and ER Kang capsules; and Yi-Yue-Kang tablets, as well as Bao-Kang strengthening tablets. It also provides water filters. The company was formerly known as Murad Chia Jei Biotechnology Co., Ltd. and changed its name to Jia Jie Biomedical Co., Ltd. in June 2019. Jia Jie Biomedical Co., Ltd. was founded in 1995 and is based in Kaohsiung, Taiwan.

Details
Name: Jia Jie Biomedical Co., Ltd.
4109
Exchange: GTSM
Founded: 1995
NT$827,232,000
68,936,000
Website: http://www.jiajiebio.com
Address: Jia Jie Biomedical Co., Ltd.
No.61, Jiuru 1st Road,
3rd Floor,
Kaohsiung,
807,
Taiwan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
GTSM 4109 Common Stock Taipei Exchange TW TWD 08. Aug 2002
Number of employees
Current staff
Staff numbers
0
Jia Jie Biomedical employees.
Industry
Personal Products
Household
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 15:46
End of day share price update: 2020/04/09 00:00
Last earnings filing: 2020/03/29
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.